Candesartan effect on inflammation in hypertension.

Abstract

The aim of this study was to evaluate the effect of candesartan on inflammatory biomarkers in hypertensive patients with and without type 2 diabetes mellitus after a standardized oral fat load (OFL). A total of 219 patients were enrolled: 106 patients were assigned to the non-diabetic hypertensive (NH) group, and 113 to the diabetic hypertensive (DH) group. All patients received candesartan therapy for 6 months and underwent a standardized OFL at baseline and after 6 months of therapy. We evaluated systolic blood pressure (SBP) and diastolic blood pressure (DBP), blood glucose (BG), triglycerides (Tg), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6) and high-sensitivity C reactive protein (Hs-CRP). At baseline, glycated hemoglobin, homeostasis model assessment insulin resistance index, BG, fasting plasma insulin, Tg, sICAM-1, IL-6 and Hs-CRP in the DH group were significantly higher, whereas high-density lipoprotein-cholesterol value was significantly lower compared to NH group. After 6 months of candesartan therapy, sICAM-1, IL-6 and Hs-CRP were significantly lower compared to baseline in both groups; furthermore, there was a significant decrease of SBP and DBP values in both groups. After the OFL administered at baseline, there was an increase of Tg, sICAM-1, IL-6 and Hs-CRP in both groups. After the OFL administered after 6 months of therapy, instead, there was no significant variation of BG, Tg or sICAM-1 value in both groups, whereas there was an increase of IL-6 and Hs-CRP compared to time 0. We observed that candesartan treatment attenuated the inflammatory answer in both groups of patients, even if more efficiently in nondiabetic ones.

• Authors: Giuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, Ilaria Ferrari, Alessia Gravina, Roberto Mereu, Ilaria Palumbo, Angela D'Angelo, Arrigo F G Cicero
• Journal: Hypertension research : official journal of the Japanese Society of Hypertension (Hypertens Res) Vol. 33 Issue 3 Pg. 209-13 (Mar 2010) ISSN: 1348-4214 [Electronic] England
• PMID: 20075928 (Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antihypertensive Agents
• Benzimidazoles
• Biomarkers
• Biphenyl Compounds
• Blood Glucose
• Dietary Fats
• Insulin
• Interleukin-6
• Tetrazoles
• Triglycerides
• Intercellular Adhesion Molecule-1
• C-Reactive Protein
• candesartan

Topics

• Aged
• Antihypertensive Agents (pharmacology, therapeutic use)
• Benzimidazoles (pharmacology, therapeutic use)
• Biomarkers (blood)
• Biphenyl Compounds
• Blood Glucose (metabolism)
• Blood Pressure (drug effects)
• C-Reactive Protein (metabolism)
• Diabetes Mellitus, Type 2 (blood, complications)
• Dietary Fats (adverse effects, pharmacology)
• Female
• Humans
• Hypertension (blood, drug therapy)
• Inflammation (blood, drug therapy, etiology)
• Insulin (blood)
• Intercellular Adhesion Molecule-1 (blood)
• Interleukin-6 (blood)
• Male
• Middle Aged
• Tetrazoles (pharmacology, therapeutic use)
• Triglycerides (blood)